Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04114630
Other study ID # CAMG334AES01
Secondary ID 2019-001820-36
Status Withdrawn
Phase Phase 3
First received
Last updated
Start date October 30, 2019
Est. completion date January 7, 2022

Study information

Verified date September 2019
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Migraine is a very common, neurological disorder, characterized by recurrent episodes of headache, potential progression to more frequent and severe attack patterns, and associated symptoms. In Spain, the prevalence rates are 12-13% and in women up to 17-18% Migraine has been shown to largely impair patient's Health-Related Quality of Life (HRQoL), affecting work, household chores, social activities and family life. Recurrent headache attacks and frequently persistent fear and concern about the next attack disrupt the patient's familial, occupational and social life, and reduce his/her expectations for career and financial future. The consequences of this loss of productivity is also shared in his/her private life with their family. For this reason, not only the clinical benefit but other dimensions as HRQoL or work affectation should be added to the study of the benefits of migraine treatment.

Migraine pathophysiology pathways may be shared with other illness, such as fibromyalgia, chronic fatigue or Irritable Bowel Syndrome (IBS) . The purpose of the present clinical trial is to evaluate whether erenumab, at a target dose of 70 mg or 140 mg for a period of 12 months, impacts Health-Related Quality of Life (HRQoL) among patients withchronic migraine (CM) or High-Frequency Episodic Migraine (HFEM) who are affected with at least one comorbidity (fibromyalgia, fatigue and IBS). Data from this study, will provide additional information to help clinicians in treating patients with migraine and other illness.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date January 7, 2022
Est. primary completion date December 6, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: key inclusion citeria

During the Screening Epoch:

1. Signed informed consent must be obtained prior to participation in the study.

2. Adults =18 years of age upon entry into screening.

3. Patient diagnosed with chronic and high -frequency episodic migraine (with or without aura) for at least 1 year prior to screening according to the International Classification of Headache Disorders-3rd Edition (ICHD-3).

4. Patient with a documented diagnosis in clinical history of one or more of the following comorbidities: chronic fatigue, fibromyalgia and/or IBS.

5. Patients previously treated with other monoclonal antibodies for migraine can be included if the appropriate washout period according to product half-life has been done for each monoclonal antibody.

During the Baseline Epoch:

1. Migraine frequency of = 10 migraine days during the Baseline Epoch, confirmed by the eDiary.

2. = 80% eDiary compliance during the Baseline Epoch.

Exclusion Criteria: Key Exclusion criteria

1. Older than 50 years of age at migraine onset.

2. Unable to differentiate migraine from other headaches.

3. History of cluster headache or hemiplegic migraine headache.

4. Used a device, or procedure within 2 months prior to the start of or during baseline or during the treatment period.

5. Use of other investigational drugs within 5 half-lives of enrollment or inappropriate washout period in case of monoclonal antibodies, or until the expected pharmacodynamic effect has returned to baseline, whichever is longer.

6. Unlikely to be able to complete all protocol required study visits or procedures, and/or to comply with all required study procedures.

7. History or evidence of any other unstable or clinically significant medical condition that in the opinion of the investigator would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.

Other protocol-defined inclusion/exclusion criteria may apply at the end.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
erenumab 70mg/mL
Unit dose: 70 mg/mL single-dose., prefilled erenumab autoinjectors. 140 mg dose = 2 x 70 mg/mL, single dose, prefilled erenumab autoinjectors

Locations

Country Name City State
Spain Novartis Investigative Site Alcorcón Madrid
Spain Novartis Investigative Site Baracaldo País Vasco
Spain Novartis Investigative Site Barcelona Cataluña
Spain Novartis Investigative Site Barcelona Cataluña
Spain Novartis Investigative Site Barcelona Cataluña
Spain Novartis Investigative Site Bilbao País Vasco
Spain Novartis Investigative Site Cadiz Andalucia
Spain Novartis Investigative Site Córdoba Andalucia
Spain Novartis Investigative Site Elda Comunidad Valenciana
Spain Novartis Investigative Site Fuenlabrada Madrid
Spain Novartis Investigative Site L'Hospitalet de Llobregat Cataluña
Spain Novartis Investigative Site Lugo Galicia
Spain Novartis Investigatice Site Madrid
Spain Novartis Investigative Site Madrid
Spain Novartis Investigative Site Madrid
Spain Novartis Investigative Site Madrid
Spain Novartis Investigative Site Palma de Mallorca Islas Baleares
Spain Novartis Investigative Site Pamplona Navarra
Spain Novartis Investigative Site Pozuelo de Alarcón Madrid
Spain Novartis Investigative Site Santa Cruz de Tenerife Islas Canarias
Spain Novartis Investigative Site Santiago de Compostela Galicia
Spain Novartis Investigative Site Sevilla Andalicía
Spain Novartis Investigative Site Sevilla Andalucía
Spain Novartis Investigational Site Valencia Comunidad Valenciana
Spain Novartis Investigative Site Valencia Comunidad Valenciana
Spain Novartis Investigative Site Valladolid Castilla León
Spain Novartis Investigative Site Zaragoza Aragón

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of patients (in the overall population and by each comorbidity) who achieve a =5-point increase in the MSQ-RFR, MSQ-RFP domains and a =8-point increase in the MSQ-EF domain of the Migraine-Specific Quality of Life Questionnaire (MSQ 2.1) MSQ 2.1 consists of 14 items that address 3 domains:(1) Role Function-Restrictive (items 1-7);(2) Role Function- Preventive (items 8-11);&(3) Emotional Function (items 12-14).Response options range from "none of the time" (value 1) to "all of the time" (value 6), & are reverse-recoded (value 6 to 1) before the domain scores are calculated.Total raw scores for each domain is the sum of the final item value for all of the items in that domain.After the total raw score is computed for each domain, they are transformed to a 0-100 scale with higher scores indicating a better health status & a positive change in scores reflecting functional improvement. Comorbidities include fibromyalgia, chronic fatigue, and/or irritable bowel syndrome (IBS) Baseline up to approximately 12 months
Secondary Association between MSQ 2.1 and other HRQoL scores in each comorbidity (fibromyalgia, chronic fatigue, and/or IBS). Correlation between HRQoL scores in migraine questionnaire (MSQ 2.1) and HRQoL scores in each comorbidity questionnaire: fibromyalgia (Fibromyalgia Impact Questionnaire, FIQ), chronic fatigue (Short Form health survey, SF-12) and IBS (Irritable Bowel Syndrome Quality of Life, IBS-QOL) in all study visits. Baseline, month 3, 6 and 12.
Secondary Mean change in HRQoL Health Related Quality of Life (HRQoL) in patients with migraine and at least once of these comorbitiy (fibromyalgia, chronic fatigue and irritable bowel syndrome [IBS]) Baseline, month 6 and 12.
Secondary Patient profile: number of migraine episodes/month This description can help to understand the baseline characteristics of patients treated with erenumab and the relation with the outcomes Baseline
Secondary Duration and exposure of 70 and 140 mg doses of erenumab Dosing information will be collected throughout the trial including dose modifications and missed doses to provide total exposure of drug over time. Baseline up to approximately 1 year
Secondary Change in the mean number of migrane days per month from baseline to month 12 • Efficacy of erenumab will be assessed by migraine days. From baseline to month 12
Secondary Change in the mean number of days of use of acute migraine-specific medication per month from baseline to month 12 • Efficacy of erenumab. From baseline to month 12.
Secondary Percentage of patients who achieve at least 50% or greater reduction in the mean number of migraine days per month from baseline to month 12. • Efficacy of erenumab. From baseline to month 12
See also
  Status Clinical Trial Phase
Completed NCT05525611 - Cabergoline as a Preventive Treatment for Chronic Migraine N/A
Completed NCT06192173 - Patent Foramen Ovale Closure in Migraine
Recruiting NCT03832998 - Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine Phase 3
Enrolling by invitation NCT04196933 - Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma N/A
Not yet recruiting NCT06428838 - Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context Phase 3
Completed NCT06304675 - Manageable Environmental Factors in Migraine
Completed NCT04084314 - Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study Phase 4
Recruiting NCT05517200 - Pilot Study for a Machine Learning Test for Migraine
Completed NCT04179474 - Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine Phase 1
Recruiting NCT04603976 - Registry for Migraine - Clinical Core Phase 4
Completed NCT03597529 - CHOCOlate MeLatonin for AdolescenT MigrainE Phase 2
Completed NCT04197349 - Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman Phase 1
Recruiting NCT05891808 - miR-155 Expression in Episodic and Chronic Migraine
Active, not recruiting NCT05064371 - Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan Phase 3
Suspended NCT04069572 - Vibratory Stimulation for the Treatment of Chronic Pain N/A
Not yet recruiting NCT04859374 - Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach N/A
Not yet recruiting NCT03083860 - Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions. N/A
Completed NCT02905227 - A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder Phase 1
Enrolling by invitation NCT02532023 - The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients Phase 4
Completed NCT02108678 - One-Day Intervention for Depression and Impairment in Migraine Patients N/A